Law Firm Probes Lisata Therapeutics’ $4 Share Sale Plus Two CVRs
LSTA•Lisata Therapeutics agreed to be acquired by Kuva Labs for $4.00 per share in cash plus two non-tradeable contingent value rights under specific performance conditions. Halper Sadeh LLC is investigating potential breaches of fiduciary duty in the deal and invites shareholders to pursue additional relief on a contingent fee basis.
1. Transaction Terms
Lisata Therapeutics has entered into a sale agreement with Kuva Labs that offers Lisata shareholders $4.00 in cash per share and two non-tradeable contingent value rights payable if specified performance milestones are met post-close.
2. Investigation Overview
Halper Sadeh LLC is investigating whether the merger terms involve breaches of fiduciary duties or deficiencies in disclosures that may have disadvantaged ordinary shareholders relative to insiders or competing offers.
3. Shareholder Rights and Options
Shareholders are encouraged to contact Halper Sadeh LLC at no cost to discuss their rights and explore potential claims for increased consideration or enhanced disclosures, with legal representation available on a contingent fee basis.
